Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RYTM, ASND, ACLX, CELC, NUVL, and represent 94.56% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: RYTM (+$42B), TVTX (+$71M), CELC (+$65M), ROIV (+$61M), MRUS (+$61M), PEN (+$48M), CNTA (+$47M), PRAX (+$43M), ABVX (+$33M), NBIX (+$27M).
- Started 21 new stock positions in ENGN, ANRO, Athira Pharma, BLTE, QURE, IRTC, Celcuity, ABVX, KOD, Biodesix. PEPG, SPRY, TEM, KRYS, GOSS, PVLA, EXAS, PYXS, ORKA, RAPP, Heartflow Inc/Sh.
- Reduced shares in these 10 stocks: VRNA (-$532M), SLNO (-$36M), AORT (-$33M), BBNX (-$26M), , EOLS (-$23M), DYN (-$22M), , CRL (-$15M), EWTX (-$14M).
- Sold out of its positions in ATHA, BDSX, CAPR, CRL, EOLS, FBRX, GMED, PODD, KALA, XBI. SLNO, RARE, HLXB.
- Perceptive Advisors was a net buyer of stock by $42B.
- Perceptive Advisors has $46B in assets under management (AUM), dropping by 1586.84%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 92 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals (RYTM) | 93.0 | $42B | +17230% | 419M | 100.99 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.5 | $216M | +12% | 1.1M | 198.81 |
|
| Arcellx Common Stock (ACLX) | 0.4 | $203M | 2.5M | 82.10 |
|
|
| Celcuity (CELC) | 0.3 | $146M | +81% | 3.0M | 49.40 |
|
| Nuvalent Inc-a (NUVL) | 0.3 | $135M | +13% | 1.6M | 86.48 |
|
| Merus N V (MRUS) | 0.3 | $127M | +91% | 1.4M | 94.15 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.3 | $122M | +13% | 9.0M | 13.59 |
|
| Roivant Sciences SHS (ROIV) | 0.2 | $112M | +121% | 7.4M | 15.13 |
|
| Meiragtx Holdings (MGTX) | 0.2 | $104M | 13M | 8.22 |
|
|
| Insmed Com Par $.01 (INSM) | 0.2 | $101M | +7% | 702k | 144.01 |
|
| Travere Therapeutics (TVTX) | 0.2 | $91M | +354% | 3.8M | 23.90 |
|
| CryoLife (AORT) | 0.2 | $86M | -27% | 2.0M | 42.34 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.2 | $83M | +107% | 1.6M | 53.00 |
|
| Immatics SHS (IMTX) | 0.2 | $80M | 9.4M | 8.52 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $75M | +170% | 3.1M | 24.25 |
|
| Solid Biosciences Com New (SLDB) | 0.2 | $73M | 12M | 6.17 |
|
|
| Protagonist Therapeutics (PTGX) | 0.2 | $68M | -4% | 1.0M | 66.43 |
|
| Neurocrine Biosciences (NBIX) | 0.1 | $63M | +76% | 450k | 140.38 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $62M | -18% | 3.8M | 16.22 |
|
| Verona Pharma Sponsored Ads (VRNA) | 0.1 | $56M | -90% | 524k | 106.71 |
|
| Penumbra (PEN) | 0.1 | $56M | +572% | 221k | 253.32 |
|
| Akero Therapeutics (AKRO) | 0.1 | $54M | +24% | 1.1M | 47.48 |
|
| Apogee Therapeutics (APGE) | 0.1 | $54M | +14% | 1.4M | 39.73 |
|
| Omada Health (OMDA) | 0.1 | $53M | 2.4M | 22.11 |
|
|
| Amicus Therapeutics (FOLD) | 0.1 | $50M | -14% | 6.4M | 7.88 |
|
| Astria Therapeutics (ATXS) | 0.1 | $47M | 6.5M | 7.28 |
|
|
| Inhibrx Biosciences (INBX) | 0.1 | $45M | +35% | 1.3M | 33.68 |
|
| Repligen Corporation (RGEN) | 0.1 | $36M | +62% | 270k | 133.67 |
|
| Zymeworks Del (ZYME) | 0.1 | $36M | +63% | 2.1M | 17.08 |
|
| Sionna Therapeutics (SION) | 0.1 | $35M | -3% | 1.2M | 29.41 |
|
| Caris Life Sciences (CAI) | 0.1 | $33M | 1.1M | 30.25 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.1 | $33M | NEW | 389k | 84.90 |
|
| Miragen Therapeutics (VRDN) | 0.1 | $32M | +226% | 1.5M | 21.58 |
|
| Cytomx Therapeutics (CTMX) | 0.1 | $31M | +38% | 9.7M | 3.19 |
|
| Boston Scientific Corporation (BSX) | 0.1 | $30M | +10% | 310k | 97.63 |
|
| Aldeyra Therapeutics (ALDX) | 0.1 | $27M | +28% | 5.2M | 5.22 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $27M | +6% | 449k | 60.66 |
|
| Immunovant (IMVT) | 0.1 | $26M | -25% | 1.6M | 16.12 |
|
| EXACT Sciences Corporation (EXAS) | 0.1 | $26M | NEW | 466k | 54.71 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.1 | $25M | NEW | 395k | 62.69 |
|
| Oruka Therapeutics (ORKA) | 0.1 | $24M | NEW | 1.3M | 19.23 |
|
| Intuitive Surgical Com New (ISRG) | 0.1 | $23M | +15% | 52k | 447.23 |
|
| Irhythm Technologies (IRTC) | 0.0 | $21M | NEW | 123k | 171.99 |
|
| Aquestive Therapeutics (AQST) | 0.0 | $21M | +71% | 3.8M | 5.59 |
|
| Spyre Therapeutics Com New (SYRE) | 0.0 | $21M | -19% | 1.2M | 16.76 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $19M | 9.9M | 1.94 |
|
|
| Axsome Therapeutics (AXSM) | 0.0 | $18M | -25% | 149k | 121.45 |
|
| Adma Biologics (ADMA) | 0.0 | $17M | -11% | 1.2M | 14.66 |
|
| Engene Holdings (ENGN) | 0.0 | $14M | NEW | 2.1M | 6.83 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.0 | $13M | +15% | 5.3M | 2.48 |
|
| Nurix Therapeutics (NRIX) | 0.0 | $13M | +29% | 1.4M | 9.24 |
|
| Rapport Therapeutics (RAPP) | 0.0 | $12M | NEW | 404k | 29.70 |
|
| Outset Med Com New (OM) | 0.0 | $12M | 833k | 14.12 |
|
|
| Nautilus Biotechnology (NAUT) | 0.0 | $11M | 13M | 0.84 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.0 | $11M | 1.4M | 7.37 |
|
|
| Kodiak Sciences (KOD) | 0.0 | $10M | NEW | 635k | 16.37 |
|
| Septerna (SEPN) | 0.0 | $10M | 542k | 18.81 |
|
|
| Gossamer Bio (GOSS) | 0.0 | $10M | NEW | 3.8M | 2.63 |
|
| Kymera Therapeutics (KYMR) | 0.0 | $9.6M | -19% | 170k | 56.60 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.0 | $8.8M | 5.4M | 1.62 |
|
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.0 | $8.7M | NEW | 6.5M | 1.34 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.0 | $8.4M | +2% | 715k | 11.75 |
|
| Xenon Pharmaceuticals (XENE) | 0.0 | $8.1M | 201k | 40.15 |
|
|
| Anteris Technologies Global (AVR) | 0.0 | $7.7M | 1.7M | 4.50 |
|
|
| Janux Therapeutics (JANX) | 0.0 | $7.2M | 293k | 24.44 |
|
|
| Ocuphire Pharma (IRD) | 0.0 | $7.1M | 4.3M | 1.65 |
|
|
| Tempus Ai Cl A (TEM) | 0.0 | $6.9M | NEW | 85k | 80.71 |
|
| Dyne Therapeutics (DYN) | 0.0 | $6.8M | -75% | 540k | 12.65 |
|
| Krystal Biotech (KRYS) | 0.0 | $6.2M | NEW | 35k | 176.53 |
|
| Beta Bionics (BBNX) | 0.0 | $5.5M | -82% | 278k | 19.87 |
|
| Crescent Biopharma (CBIO) | 0.0 | $5.4M | 454k | 11.89 |
|
|
| Heartflow Inc/Sh | 0.0 | $5.0M | NEW | 150k | 33.66 |
|
| Rapt Therapeutics Com New (RAPT) | 0.0 | $4.7M | 184k | 25.79 |
|
|
| Pepgen (PEPG) | 0.0 | $3.8M | NEW | 830k | 4.62 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.0 | $3.7M | NEW | 50k | 74.00 |
|
| Scpharmaceuticals (SCPH) | 0.0 | $3.3M | +16% | 583k | 5.67 |
|
| Viking Therapeutics (VKTX) | 0.0 | $2.8M | -72% | 106k | 26.28 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.0 | $2.6M | NEW | 1.2M | 2.22 |
|
| Athira Pharma | 0.0 | $2.2M | NEW | 540k | 4.14 |
|
| Silverback Therapeutics Put Option (SPRY) | 0.0 | $2.0M | NEW | 200k | 10.05 |
|
| Trinity Biotech Spons Adr New (TRIB) | 0.0 | $1.9M | 1.8M | 1.04 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.0 | $1.8M | 140k | 12.71 |
|
|
| Envveno Medical (NVNO) | 0.0 | $1.6M | +36% | 1.8M | 0.91 |
|
| Lyra Therapeutics Com New (LYRA) | 0.0 | $1.5M | -10% | 229k | 6.53 |
|
| Uniqure Nv SHS (QURE) | 0.0 | $1.2M | NEW | 20k | 58.37 |
|
| Lexeo Therapeutics (LXEO) | 0.0 | $929k | 140k | 6.64 |
|
|
| Biodesix | 0.0 | $821k | NEW | 109k | 7.55 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.0 | $625k | NEW | 155k | 4.02 |
|
| Apyx Medical Corporation (APYX) | 0.0 | $321k | 150k | 2.14 |
|
|
| Ensysce Biosciences Com New (ENSC) | 0.0 | $205k | 87k | 2.37 |
|
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $75k | 250k | 0.30 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $3.0k | 167k | 0.02 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2025 Q3 filed Nov. 14, 2025
- Perceptive Advisors 2025 Q2 filed Aug. 14, 2025
- Perceptive Advisors 2025 Q1 restated filed Aug. 6, 2025
- Perceptive Advisors 2025 Q1 filed May 15, 2025
- Perceptive Advisors 2024 Q4 filed Feb. 14, 2025
- Perceptive Advisors 2024 Q3 filed Nov. 14, 2024
- Perceptive Advisors 2024 Q2 restated filed Aug. 16, 2024
- Perceptive Advisors 2024 Q2 filed Aug. 14, 2024
- Perceptive Advisors 2024 Q1 restated filed Aug. 6, 2024
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023
- Perceptive Advisors 2023 Q2 restated filed Aug. 24, 2023
- Perceptive Advisors 2023 Q2 filed Aug. 14, 2023
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023